AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
Minority interest | - | - | - | 0.00000M | 0.00000M |
Net income | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
Selling general administrative | 2676.00M | 1283.00M | 661.00M | 342.00M | 213.69M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
Reconciled depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
Ebit | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1612.39M |
Ebitda | 7043.00M | 3463.00M | 6756.00M | 2897.00M | 1699.98M |
Depreciation and amortization | 686.00M | 445.00M | 443.00M | 259.00M | 87.60M |
Non operating income net other | - | - | - | 0.00000M | 0.00000M |
Operating income | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1380.28M |
Other operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
Interest expense | 21.00M | 13.00M | 10.00M | 7.00M | 0.42M |
Tax provision | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
Interest income | 324.00M | 197.00M | 184.00M | 348.00M | 62.92M |
Net interest income | 303.00M | 184.00M | 174.00M | 334.00M | 62.51M |
Extraordinary items | - | - | - | 0.00000M | 0.00000M |
Non recurring | - | - | - | 0.00000M | 0.00000M |
Other items | - | - | - | 0.00000M | 0.00000M |
Income tax expense | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
Total revenue | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
Total operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
Cost of revenue | - | - | - | 0.00000M | 0.00000M |
Total other income expense net | 678.00M | 965.00M | -409.00000M | 221.00M | 231.69M |
Discontinued operations | - | - | - | 0.00000M | 0.00000M |
Net income from continuing ops | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
Net income applicable to common shares | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.00M |
Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 30278.00M | 24627.00M | 21143.00M | 15144.00M | 8461.00M |
Intangible assets | 146.00M | 254.00M | 338.00M | 470.00M | 470.36M |
Earning assets | - | - | - | - | - |
Other current assets | - | - | - | 10398.00M | 0.00000M |
Total liab | 2837.00M | 2431.00M | 2022.00M | 1096.00M | 446.64M |
Total stockholder equity | 27441.00M | 22196.00M | 19121.00M | 14048.00M | 8014.36M |
Deferred long term liab | - | - | - | 0.00000M | 0.00000M |
Other current liab | 1716.00M | 1130.00M | 1185.00M | 912.00M | 443.35M |
Common stock | 66.00M | 66.00M | 66.00M | 65.00M | 61.50M |
Capital stock | 66.00M | 66.00M | 66.00M | 65.00M | 61.50M |
Retained earnings | 14968.00M | 10020.00M | 7107.00M | 2130.00M | -197.45900M |
Other liab | 491.00M | 500.00M | 492.00M | 3.00M | 3.00M |
Good will | - | - | - | 0.00000M | 0.00000M |
Other assets | 300.00M | 291.00M | 197.00M | 150.00M | 396.00M |
Cash | 9893.00M | 8957.00M | 7260.00M | 3552.00M | 532.91M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 1823.00M | 1568.00M | 1253.00M | 938.00M | 443.35M |
Current deferred revenue | 33.00M | 26.00M | 26.00M | - | - |
Net debt | -9296.00000M | -8532.00000M | -6941.00000M | -3371.00000M | -532.90700M |
Short term debt | 74.00M | 62.00M | 42.00M | 26.00M | 0.00000M |
Short long term debt | - | - | - | 0.00000M | 0.00000M |
Short long term debt total | 597.00M | 425.00M | 319.00M | 181.00M | 0.00000M |
Other stockholder equity | 12309.00M | 12029.00M | 11894.00M | 11755.00M | 8058.61M |
Property plant equipment | 1322.00M | 975.00M | 736.00M | 414.00M | 162.00M |
Total current assets | 28377.00M | 22736.00M | 18791.00M | 13961.00M | 7433.02M |
Long term investments | 133.00M | 371.00M | 1081.00M | 149.00M | 0.00000M |
Net tangible assets | 27295.00M | 21942.00M | 18783.00M | 13578.00M | 7544.00M |
Short term investments | 12431.00M | 10381.00M | 8819.00M | 7419.00M | 5573.19M |
Net receivables | 6053.00M | 3398.00M | 2712.00M | 2990.00M | 1326.93M |
Long term debt | - | - | - | 0.00000M | 0.00000M |
Inventory | - | - | - | -10398.00000M | 0.00000M |
Accounts payable | - | 350.00M | - | 0.00000M | 0.00000M |
Total permanent equity | - | - | - | 0.00000M | 0.00000M |
Noncontrolling interest in consolidated entity | - | - | - | 0.00000M | 0.00000M |
Temporary equity redeemable noncontrolling interests | - | - | - | 0.00000M | 0.00000M |
Accumulated other comprehensive income | 98.00M | 81.00M | 54.00M | 98.00M | 91.71M |
Additional paid in capital | - | - | - | 0.00000M | 0.00000M |
Common stock total equity | - | - | 66.00M | 65.00M | 61.50M |
Preferred stock total equity | - | - | - | 0.00000M | 0.00000M |
Retained earnings total equity | - | - | - | 0.00000M | 0.00000M |
Treasury stock | - | - | - | 0.00000M | 0.00000M |
Accumulated amortization | - | - | - | 0.00000M | 0.00000M |
Non currrent assets other | 48.00M | 27.00M | 20.00M | 11.00M | 9.62M |
Deferred long term asset charges | - | - | - | 0.00000M | 0.00000M |
Non current assets total | 1901.00M | 1891.00M | 2352.00M | 1183.00M | 1027.97M |
Capital lease obligations | 597.00M | 425.00M | 319.00M | 181.00M | 0.00000M |
Long term debt total | - | - | - | 155.00M | 0.00000M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -2761.00000M | -709.00000M | -2351.00000M | -1983.00000M | -1777.55300M |
Change to liabilities | 283.00M | 304.00M | 681.00M | 440.00M | 134.00M |
Total cashflows from investing activities | -2761.00000M | -961.00000M | -2351.00000M | -1983.00000M | -1778.00000M |
Net borrowings | -73.00000M | -58.00000M | -44.00000M | -31.00000M | -31.00000M |
Total cash from financing activities | -789.00000M | -420.00000M | 71.00M | 3660.00M | -70.90100M |
Change to operating activities | - | -770.00000M | -770.00000M | -770.00000M | -770.00000M |
Net income | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
Change in cash | 936.00M | 1697.00M | 3708.00M | 3019.00M | -814.63800M |
Begin period cash flow | 8957.00M | 7260.00M | 3552.00M | 533.00M | 1347.55M |
End period cash flow | 9893.00M | 8957.00M | 7260.00M | 3552.00M | 532.91M |
Total cash from operating activities | 3912.00M | 2228.00M | 6433.00M | 1326.00M | 1014.79M |
Issuance of capital stock | - | 0.00000M | 0.00000M | 3873.00M | 0.31M |
Depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
Other cashflows from investing activities | - | - | - | -1872.00000M | -1300.18700M |
Dividends paid | - | - | - | 0.00000M | 0.00000M |
Change to inventory | - | - | - | 0.00000M | 0.00000M |
Change to account receivables | -2213.00000M | -1074.00000M | 306.00M | -0.00006M | -0.00004M |
Sale purchase of stock | -908.00000M | -447.00000M | 0.00000M | 0.00000M | -146.17500M |
Other cashflows from financing activities | 192.00M | 85.00M | 115.00M | -182.00000M | 74.96M |
Change to netincome | -78.00000M | -314.00000M | 422.00M | 211.00M | 89.00M |
Capital expenditures | 317.00M | 252.00M | 307.00M | 111.00M | 477.37M |
Change receivables | - | - | - | 0.00000M | 0.00000M |
Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
Change in working capital | -1930.00000M | -770.00000M | 987.00M | -1218.00000M | -634.37200M |
Stock based compensation | 439.00M | 310.00M | 200.00M | 147.00M | 90.76M |
Other non cash items | -1994.00000M | -997.00000M | 409.00M | -216.00000M | -231.68800M |
Free cash flow | 3595.00M | 1976.00M | 6126.00M | 1215.00M | 537.42M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
GMAB Genmab AS |
-1.01 3.55% | 27.46 | 32.21 | 21.32 | 1.19 | 4.39 | 0.95 | 3.00 |
NVO Novo Nordisk A/S |
-0.37 0.29% | 125.79 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
-3.3 2.60% | 123.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
-3.06 0.76% | 397.70 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
CSLLY CSL Ltd |
0.06 0.07% | 90.16 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Kalvebod Brygge 43, Copenhagen, Denmark, 1560
Name | Title | Year Born |
---|---|---|
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO | 1961 |
Mr. Anthony Pagano | Exec. VP & CFO | 1978 |
Mr. Anthony Mancini | Exec. VP & COO | 1971 |
Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer | 1958 |
Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines | 1973 |
Dr. Mijke Zachariasse Ph.D. | Director of Protein Production & Chemist and Non-Independent Director | 1974 |
Dr. Rima Bawarshi Nassar Ph.D. | VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director | 1953 |
Mr. Peter Ros | Sr. Director of Fin. & Accounting | NA |
Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations | NA |
Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer | 1961 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).